Article
Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Molecular cancer therapeutics - 1 Jul 2016
Bonnevaux Hélène, Lemaitre Olivier, Vincent Loic, Levit Mikhail N, Windenberger Fanny, Halley Frank, Delorme Cécile, Lengauer Christoph, Garcia-Echeverria Carlos, Virone-Oddos Angela
Abstract excerpt
Class IA PI3K pathway activation resulting from PTEN deficiency has been associated with lack of sensitivity of melanoma to BRAF kinase inhibitors. Although previous studies have shown synergistic activity when pan-PI3K inhibitors were combined with MAPK inhibitors in the treatment of melanoma ex...
Topics
- Administration, Oral
- Animals
- Cell Line, Tumor
- Class Ia Phosphatidylinositol 3-Kinase
- Disease Models, Animal
- Drug Synergism
- Female
- Humans
- Indoles
- MAP Kinase Kinase 1